Another generic drugmaker settles price-fixing probe

(By Maia Anderson for Becker’s Hospital Review)

Rising Pharmaceuticals agreed to pay more than $3 million to settle claims it conspired to fix prices for a hypertension drug.

The Saddle Brook, N.J.-based generic drugmaker signed a deferred prosecution agreement with the U.S. Justice Department for its part in a criminal antitrust conspiracy that took place  from April 2014 until at least September 2015.   Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.